Adamed Discovery S.A.

AI-driven drug discovery at scale

A Polish company running SHIELD and ONCO51 biologics trials across integrated R&D centres and 19 therapeutic areas

Industry
TechBio Drug Discovery
Headquarters
Kajetany, Poland
Public information as of
January 2026

A4BEE prepared this analysis from publicly available sources. It reflects our own reading of Adamed Discovery S.A.'s published strategy and is not endorsed by, or produced in cooperation with, Adamed Discovery S.A.. Company website

Strategic priorities

Adamed Discovery is a Polish TechBio company that sits within the Adamed Group but operates with distinct R&D capabilities — molecular design, biologics manufacturing, and computational biology — that are being integrated into a unified digital platform. The company is developing first-in-class multi-specific biologics including ONCO51 targeting colorectal cancer, SHIELD for immuno-oncology, and INHAPRO for inflammatory diseases, with the goal of advancing from traditional experimental biology toward a model where computational biology, AI, and automated laboratory workflows are central to drug discovery rather than supportive tools.

The core digital challenge is the fragmentation of the data path from bioreactor sensor to scientist dashboard — despite the Labgears platform initiative, multi-vendor equipment creates data islands that prevent the AI and ML applications the computational biology team needs. The company is also managing the legacy equipment integration debt from the Pabianice and Ksawerow manufacturing sites, where extensive existing investments mean significant equipment fleet lacks modern communication interfaces.

Adamed Discovery is preparing for GxP validation of AI-driven tools — every digital tool and automated process must meet FDA, EMA, and GMP safety and quality standards, with the validation overhead often outweighing the efficiency gains in the near term.

Challenges we see

  • Digital Integration

    Data islands preventing AI and ML applications

    Despite the Labgears platform initiative, data from multi-vendor equipment — bioreactors, chromatography systems, analytical instruments — flows through disconnected systems that prevent the computational biology team from building the unified datasets required for AI model training. Manual data entry and Excel workbooks persist alongside the Labgears platform.

    When the data required for ML model training is scattered across incompatible systems, the computational biology team spends more time on data engineering than on model development — the AI-driven drug discovery mission is slowed by data infrastructure limitations that the Labgears platform has not resolved.

  • Operations Manufacturing

    Legacy OT equipment with no modern communication interfaces

    Extensive investments in existing Pabianice and Ksawerow manufacturing sites mean significant legacy equipment fleet lacks modern APIs or communication interfaces — requiring custom retrofitting to integrate into the Industry 4.0 ecosystem. The accumulated integration debt creates ongoing maintenance costs and cybersecurity vulnerabilities.

    When legacy equipment requires custom engineering for every new digital tool integration, the cost and time of digital transformation projects increases with each piece of equipment — the integration debt compounds with every new system added to the portfolio.

  • Operations Manufacturing

    ONCO51 scale-up from 1L research to 50L clinical manufacturing

    As ONCO51 progresses through clinical trials, achieving process consistency across different scales — 1L research bioreactors to 50L pilot to commercial volumes — for sensitive biologics manufacturing presents exponentially increasing complexity. The biological variability of mammalian cell culture makes scale-up particularly challenging.

    When ONCO51 scale-up encounters process variability at the pilot stage, the clinical supply timeline is at risk — the investment in the clinical trial programme depends on manufacturing processes that are not yet characterised at the scale required for Phase 2.

  • Compliance Regulatory

    AI-driven quality tools requiring GxP validation

    Every AI-driven digital tool and automated process must be validated to meet FDA, EMA, and GMP safety and quality standards. The regulatory overhead of GxP validation for AI tools — algorithm documentation, validation protocol execution, ongoing monitoring — often outweighs the efficiency gains in the near term.

    When the regulatory validation overhead for an AI tool exceeds the productivity gain it delivers, the business case for deploying it in a GxP context fails — the tool is used in the research environment but not in the manufacturing environment where it would have the greatest impact.

  • Digital Operations

    Fourfold microbiology laboratory capacity expansion

    The expansion of the microbiology laboratory in Pabianice fourfold for inhaled drug development creates unsustainable demand for manual cell counting, classification, and infection detection — with technicians performing monotonous tasks prone to human error and slow reaction times that cannot scale to the expanded laboratory capacity.

    When the expanded microbiology laboratory continues to rely on manual cell counting and classification, the expanded capacity generates the same throughput as before the investment — the capacity expansion does not deliver its intended productivity improvement.

Opportunities, by urgency and business impact

Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.

Source: A4BEE analysis of public sources
  1. MTP-based modular lab architecture for equipment interoperability

    Laboratory equipment from multiple vendors — bioreactors, chromatography systems, analytical instruments — uses different communication protocols, creating fragmented data chains where manual data entry or disconnected data islands persist despite digital platform investments.

    Implement MTP (VDI/VDE/NAMUR 2658) standard across Kajetany and production facilities to enable Plug and Produce modularity — where equipment integrates into central orchestration without custom programming, and the Labgears platform can communicate with any new instrument through the standardised interface.

    • Adamed Discovery equipment ecosystem and Labgears platform assessment
    • Current multi-vendor equipment communication protocol audit
  2. Secure OT gateway and Zero Trust architecture for legacy assets

    Air-gapped legacy equipment in Pabianice and Ksawerow requires manual USB data transfers creating security vulnerabilities, while lack of secure IoT connectivity prevents real-time monitoring and integration with cloud analytics platforms.

    Deploy secure IoT gateways with Zero Trust security principles at the OT layer — connecting legacy equipment to central data platforms while protecting automated production lines from cyber threats, without requiring full hardware replacement of the legacy equipment fleet.

    • Adamed Discovery OT security assessment and legacy equipment inventory
    • Zero Trust architecture implementation pathway for pharmaceutical manufacturing
  3. Digital twin for ONCO51 bioprocess optimisation and scale-up

    Bioprocess optimisation for ONCO51 relies on wet-lab trial and error with post-experiment data analysis, lacking digital twin simulation to predict manufacturing outcomes or identify optimal conditions across the 1L-to-50L scale-up transition.

    Develop digital twin models for ONCO51 manufacturing processes enabling virtual experimentation to identify optimal growth conditions — reducing the physical experimental cycles required to characterise the scale-up process and accelerating the timeline to Phase 2 clinical supply.

    • Adamed Discovery ONCO51 clinical trial timeline and manufacturing roadmap
    • Current bioprocess development approach and scale-up characterisation plan
  4. AI vision systems for microbiology laboratory automation

    Fourfold microbiology laboratory expansion creates unsustainable manual cell counting and infection detection workload — technicians perform monotonous tasks prone to human error that cannot scale to the laboratory capacity the expansion investment requires.

    Implement AI-driven vision systems for automated cell counting, classification, and early contamination detection — protecting large-scale ONCO51 production batches from failure and enabling the fourfold capacity expansion to deliver its intended productivity improvement.

    • Adamed Discovery microbiology laboratory expansion plan and capacity analysis
    • Current manual cell counting and classification workflow assessment
  5. Ontology-driven data platform across 19 therapeutic areas

    Critical bioprocess KPIs are tracked separately from live process trends, with Labgears still evolving while scientific data remains fragmented across 19 therapeutic areas — preventing the unified cross-programme analysis that the AI-driven drug discovery mission requires.

    Build an ontology-driven Industrial Data Platform with semantic data structures ensuring contextualised, machine-readable data from collection point — enabling cross-therapeutic-area queries and providing the ML-ready data foundation that the TechBio computational biology mission requires.

    • Adamed Discovery therapeutic area portfolio and data fragmentation assessment
    • Current Labgears platform capabilities and gaps for cross-area data analysis

What we'd propose

  • Digital Lab

    MTP-Based Modular Laboratory Architecture

    We implement MTP (VDI/VDE/NAMUR 2658) standard across Adamed Discovery's bioreactor, chromatography, and analytical equipment ecosystem — enabling Plug and Produce modularity where new instruments integrate into the Labgears platform without custom programming, and every equipment vendor's communication protocol is handled by the standardised MTP interface layer.

    • MTP equipment module library for all instrument types

      Every instrument type has a standardised MTP integration module

      Define MTP-compliant equipment modules for the bioreactors, chromatography systems, UPLC/MS, and cell counters in the Kajetany and Pienkov laboratories — each module handles the vendor-specific communication protocol and exposes a standardised interface to the Labgears platform.

    • Plug and Produce commissioning for new instruments

      New instruments commissioned in hours rather than weeks

      Configure the Plug and Produce commissioning workflow — when a new instrument is added to a laboratory, the MTP module is loaded and the instrument is operational in the Labgears platform within hours rather than requiring the custom integration engineering that currently delays new equipment deployment.

    • Cross-site MTP deployment for Pabianice pilot plant

      Pabianice pilot bioreactors connected via MTP standard

      Extend the MTP standard deployment to the Pabianice 50L mammalian and 100L bacterial pilot bioreactors — connecting the pilot plant to the same Labgears platform architecture used in the Kajetany and Pienkov research laboratories.

    • The computational biology team can access data from any instrument through the standardised MTP interface — the AI model training datasets are no longer limited by the instruments that have custom integrations.
    • New equipment is deployed faster because MTP-compliant modules eliminate custom integration engineering — the laboratory expansion plans are not delayed by the integration work that currently follows every new instrument purchase.
    • The Labgears platform scales with the organisation because new capabilities are added through module configuration rather than custom development — the platform grows with the drug discovery programme without accumulating integration debt.
  • Digital CDMO

    Secure OT Gateway and Zero Trust Architecture

    We deploy secure IoT gateways and Zero Trust network architecture for Adamed Discovery's legacy OT environment — connecting air-gapped manufacturing equipment to the central data platform while enforcing identity-aware access controls, protecting automated production lines from the cyber threat vectors that target pharmaceutical manufacturing facilities.

    • Zero Trust OT gateway deployment

      Legacy OT equipment connected with identity-aware security controls

      Deploy Zero Trust OT gateways at the boundary between the Pabianice and Ksawerow OT networks and the enterprise IT systems — each device is authenticated before receiving network access, and the principle of least privilege restricts what each authenticated device can communicate with.

    • Continuous OT security monitoring and alerting

      OT network anomalies detected and alerted in real time

      Configure OT security monitoring that tracks network traffic patterns in the Pabianice and Ksawerow manufacturing networks — identifying anomalous communication patterns that may indicate a cyber intrusion and alerting the security operations team before the threat propagates.

    • Secure remote access for OT equipment maintenance

      Maintenance engineers access OT systems with full audit trails

      Implement secure remote access for equipment vendors and internal maintenance engineers — each remote access session is authenticated, logged, and audited, enabling remote maintenance support without creating persistent remote access vulnerabilities.

    • The OT network is protected from the lateral movement attacks that have compromised other pharmaceutical manufacturing facilities — the Zero Trust architecture ensures that a compromised IT system cannot be used as a pivot point to reach OT control systems.
    • Remote maintenance support is enabled without the security risk of persistent remote access — equipment vendors can diagnose and resolve issues remotely with full audit trails, reducing on-site visit requirements and the associated travel costs.
    • The cybersecurity posture is demonstrable to pharmaceutical clients and regulatory auditors — the NIS2 and IEC 62443 compliance requirements are met through the architectural controls rather than through after-the-fact documentation.
  • Enterprise AI

    Digital Twin for ONCO51 Bioprocess Optimisation

    We develop physics-based and data-driven digital twin models for Adamed Discovery's ONCO51 biologics manufacturing process — enabling virtual experimentation to identify optimal growth conditions, predict scale-up behaviour, and reduce the physical experimental cycles required to characterise the manufacturing process for Phase 2 clinical supply.

    • Cell culture digital twin for mammalian bioprocess

      ONCO51 cell culture behaviour predicted in simulation

      Build the cell culture digital twin for the ONCO51 mammalian expression system — combining first-principles models of cell metabolism with empirical data from the Kajetany bioreactor runs to predict cell growth, viability, and product quality under varied process conditions.

    • Scale-up simulation from 1L to 50L bioreactors

      50L scale performance predicted from 1L research data

      Configure the scale-up simulation models that predict 50L pilot bioreactor performance from 1L research bioreactor data — identifying the mixing, oxygen transfer, and shear stress parameters that must be controlled differently at scale to maintain product quality.

    • Digital twin validation and continuous model updating

      Digital twin accuracy verified with every physical batch

      Build the model validation pipeline that compares digital twin predictions against actual batch results — continuously recalibrating the model parameters as more physical data accumulates, improving prediction accuracy with each completed batch.

    • The ONCO51 clinical supply timeline is protected because scale-up risks are identified and addressed in simulation rather than through physical trial batches — the Phase 2 manufacturing process is characterised faster and with fewer failed batches.
    • Manufacturing process development costs are reduced because fewer physical experiments are required to characterise the operating parameter space — the experimental budget for ONCO51 is stretched further because each physical experiment is informed by simulation results.
    • The digital twin platform becomes an asset for subsequent biologics programmes — the SHIELD and INHAPRO development timelines benefit from the same modelling infrastructure, multiplying the value of the initial platform investment.
  • Digital Lab

    AI Vision Systems for Microbiology Laboratory Automation

    We implement AI-driven computer vision systems for Adamed Discovery's expanded microbiology laboratory — automated cell counting, classification, and early contamination detection that enables the fourfold laboratory capacity expansion to deliver its intended productivity improvement without proportional headcount expansion.

    • Automated cell counting with computer vision

      Cell density measured automatically from microscopy images

      Deploy computer vision models for automated cell counting from microscopy images — eliminating the manual counting step that currently limits microbiology laboratory throughput and introducing the objective, reproducible measurement that automated process control requires.

    • Contamination detection and early warning alerting

      Contamination identified from image analysis before it spreads

      Train contamination detection models on historical microbiology image data — identifying the visual signatures of bacterial and fungal contamination in cell culture before the contamination becomes visible to the naked eye or spreads to other culture vessels.

    • Microbiology results integrated with LIMS and batch records

      Microbiology results flowing automatically to LIMS and batch records

      Configure the integration between the computer vision system and LIMS — microbiology results are captured, attributed, and transferred to the batch record automatically, eliminating the manual transcription step that currently creates ALCOA+ compliance risks.

    • The fourfold microbiology capacity expansion delivers its intended productivity improvement — the laboratory throughput scales with the investment rather than being limited by manual counting throughput.
    • Contamination-related batch failures decrease because contamination is detected earlier — the ONCO51 production batches are protected from the culture failures that would delay the clinical trial programme.
    • Microbiologist time is redirected from monotonous counting to interpretation and investigation — the skilled microbiology team focuses on the analytical work that requires human expertise rather than on repetitive measurement tasks.
  • Enterprise AI

    Ontology-Driven Scientific Data Platform

    We build an ontology-driven Industrial Data Platform for Adamed Discovery that unifies scientific data across all 19 therapeutic areas — semantic data structures that connect molecular design, assay results, bioprocess parameters, and clinical outcomes in a machine-readable knowledge graph, providing the ML-ready data foundation that the TechBio computational biology mission requires.

    • Biological ontology framework for drug discovery data

      Molecular designs, assay results, and process parameters in one ontology

      Define the ontology framework that structures Adamed Discovery's drug discovery data — connecting genetic sequences, protein expression measurements, assay results, bioprocess parameters, and clinical outcomes in a biologically meaningful knowledge graph that enables cross-area queries.

    • Automated data ingestion from Labgears and external databases

      All data sources connected to the ontology platform automatically

      Build automated data pipelines from Labgears, external sequence databases, clinical trial databases, and partner data systems — every data source that contributes to drug discovery decisions is connected to the ontology platform with automated quality checks at ingestion.

    • ML-ready data warehouse with automated feature engineering

      Data prepared for ML model training automatically

      Configure the ML-ready data warehouse that structures the ontology data for machine learning applications — automated feature engineering pipelines prepare the data for model training without requiring the data engineering effort that currently slows every new ML project.

    • The computational biology team can pursue ML projects without the months of data engineering that currently precede every model development effort — the ML-ready data warehouse reduces the barrier to applying AI to drug discovery problems.
    • Cross-therapeutic-area insights are possible because the ontology connects data across all 19 areas — patterns that would be invisible in individual programme datasets become apparent when the full portfolio is queried.
    • The data platform accelerates the TechBio mission transition — the biological data assets that are built through this platform become a compounding strategic advantage as the breadth and depth of the ontology grows.

Digital maturity: today and target

Scored out of 100 across six dimensions. The target is what Adamed Discovery S.A.'s own published ambition implies — not a perfect score.

Source: A4BEE analysis of public sources
Data Integration 45 → 85
Multi-vendor equipment at Kajetany, Pienkov, and Pabianice creates data islands that prevent the unified datasets required for AI model training. Manual data entry and Excel workbooks persist alongside the Labgears platform. The MTP standard integration required to connect all laboratory equipment has not been deployed.
Process Automation 55 → 90
Fourfold microbiology laboratory expansion is underway without automated cell counting and contamination detection. The AI vision systems required to enable the capacity expansion to deliver its intended productivity improvement have not been deployed.
Predictive Analytics 35 → 80
Digital twin models for ONCO51 bioprocess optimisation have not been built. The computational biology team relies on post-experiment analysis rather than predictive simulation. The scale-up from 1L research to 50L pilot is characterised through physical experimentation rather than in-silico prediction.
OT/IT Convergence 40 → 85
Legacy equipment at Pabianice and Ksawerow is air-gapped from enterprise IT systems. Manual USB data transfers create security vulnerabilities. The Zero Trust OT gateway architecture required to connect legacy equipment securely has not been deployed.
Regulatory Compliance Automation 50 → 85
AI-driven tools require GxP validation that is not yet in place. The validation framework for AI models in GxP contexts — algorithm documentation, ongoing monitoring, model change control — has not been developed or approved by the regulatory affairs team.
Cybersecurity Maturity 45 → 80
Legacy OT equipment creates cybersecurity vulnerabilities that Zero Trust architecture would address. The NIS2 and IEC 62443 compliance requirements for pharmaceutical OT networks have not been formally assessed or implemented.

Check this yourself

Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.

Think we've read this right?

Talk to us

Related reading

This is an independent analysis prepared by A4BEE from publicly available information as of January 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with Adamed Discovery S.A., and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].